PensionDanmark Pensionsforsikringsaktieselskab boosted its position in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN – Free Report) by 17.6% during the 2nd quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 24,190 shares of the biopharmaceutical company’s stock after purchasing an additional 3,619 shares during the quarter. PensionDanmark Pensionsforsikringsaktieselskab’s holdings in Regeneron Pharmaceuticals were worth $15,083,000 as of its most recent filing with the Securities and Exchange Commission (SEC).
Several other large investors have also recently bought and sold shares of REGN. WPG Advisers LLC increased its holdings in shares of Regeneron Pharmaceuticals by 312.5% in the fourth quarter. WPG Advisers LLC now owns 33 shares of the biopharmaceutical company’s stock worth $25,000 after purchasing an additional 25 shares during the period. Western Wealth Management LLC bought a new stake in Regeneron Pharmaceuticals during the first quarter valued at $26,000. SHP Wealth Management purchased a new position in Regeneron Pharmaceuticals during the fourth quarter worth about $26,000. Titan Wealth CI Ltd purchased a new position in Regeneron Pharmaceuticals during the fourth quarter worth about $29,000. Finally, Kemnay Advisory Services Inc. bought a new position in Regeneron Pharmaceuticals in the 4th quarter worth about $31,000. 83.31% of the stock is owned by institutional investors.
Trending Headlines about Regeneron Pharmaceuticals
Here are the key news stories impacting Regeneron Pharmaceuticals this week:
- Positive Sentiment: Barclays maintained its Buy rating on Regeneron. The reaffirmed bullish view provides support for REGN, particularly after the company’s recent earnings beat, which included revenue growth and earnings per share well above consensus. Barclays Keeps Their Buy Rating on Regeneron
- Neutral Sentiment: Intellia Therapeutics reported lower revenue because of reduced Regeneron collaboration revenue. Intellia’s second-quarter revenue declined 46.2%, but the item reflects Intellia’s financial results rather than a newly announced change in Regeneron’s pipeline or partnership strategy. NTLA Q2 Earnings In Line, Top Line Misses on Lower Regeneron Revenues
- Negative Sentiment: Several law firms reiterated notices about a pending securities class action against Regeneron. The lawsuit concerns alleged disclosure issues surrounding the failed Phase 3 melanoma trial, which reportedly led to a substantial market-value loss. Investors who purchased REGN shares during the August 1, 2025–May 15, 2026 class period have until September 14, 2026 to seek lead-plaintiff status. The repeated notices add legal and reputational risk but do not indicate a new lawsuit-related financial liability. Regeneron Class Action Lawsuit Deadline Notice
Insider Activity at Regeneron Pharmaceuticals
Wall Street Analyst Weigh In
Several analysts have weighed in on REGN shares. Wells Fargo & Company raised their price target on Regeneron Pharmaceuticals from $700.00 to $750.00 and gave the company an “equal weight” rating in a report on Friday, July 31st. BMO Capital Markets decreased their price objective on shares of Regeneron Pharmaceuticals from $900.00 to $730.00 and set an “outperform” rating on the stock in a research report on Monday, May 18th. Citigroup raised their target price on shares of Regeneron Pharmaceuticals from $700.00 to $740.00 and gave the company a “neutral” rating in a research note on Monday, August 3rd. Cantor Fitzgerald boosted their price target on shares of Regeneron Pharmaceuticals from $750.00 to $795.00 and gave the stock an “overweight” rating in a research note on Friday, July 31st. Finally, Piper Sandler lowered their price objective on shares of Regeneron Pharmaceuticals from $855.00 to $854.00 and set an “overweight” rating on the stock in a research report on Thursday, July 9th. One research analyst has rated the stock with a Strong Buy rating, sixteen have assigned a Buy rating and ten have issued a Hold rating to the company’s stock. According to data from MarketBeat, the company currently has an average rating of “Moderate Buy” and an average target price of $797.75.
Read Our Latest Stock Analysis on Regeneron Pharmaceuticals
Regeneron Pharmaceuticals Stock Performance
NASDAQ:REGN opened at $784.36 on Friday. The business has a 50 day moving average of $657.28 and a 200 day moving average of $712.33. The company has a market capitalization of $82.92 billion, a price-to-earnings ratio of 19.39, a PEG ratio of 1.32 and a beta of 0.22. Regeneron Pharmaceuticals, Inc. has a 1-year low of $541.00 and a 1-year high of $821.11. The company has a debt-to-equity ratio of 0.06, a current ratio of 3.34 and a quick ratio of 2.78.
Regeneron Pharmaceuticals (NASDAQ:REGN – Get Free Report) last issued its quarterly earnings results on Thursday, July 30th. The biopharmaceutical company reported $14.29 EPS for the quarter, beating analysts’ consensus estimates of $10.16 by $4.13. The business had revenue of $4.29 billion for the quarter, compared to analysts’ expectations of $3.82 billion. Regeneron Pharmaceuticals had a net margin of 27.86% and a return on equity of 13.47%. The business’s quarterly revenue was up 16.7% on a year-over-year basis. During the same period last year, the business earned $12.81 earnings per share. On average, sell-side analysts predict that Regeneron Pharmaceuticals, Inc. will post 44.25 earnings per share for the current fiscal year.
Regeneron Pharmaceuticals Announces Dividend
The firm also recently disclosed a quarterly dividend, which will be paid on Monday, August 31st. Stockholders of record on Tuesday, August 18th will be paid a $0.94 dividend. The ex-dividend date of this dividend is Tuesday, August 18th. This represents a $3.76 dividend on an annualized basis and a dividend yield of 0.5%. Regeneron Pharmaceuticals’s dividend payout ratio is 9.29%.
About Regeneron Pharmaceuticals
Regeneron Pharmaceuticals, Inc (NASDAQ: REGN) is a U.S.-based biotechnology company founded in 1988 and headquartered in Tarrytown, New York. It focuses on discovering, developing, manufacturing and commercializing medicines for serious medical conditions. The company combines laboratory research, clinical development and in-house manufacturing to advance a pipeline of biologic therapies across multiple therapeutic areas.
Regeneron is known for its proprietary drug discovery technologies, including its VelocImmune platform, which is used to generate fully human monoclonal antibodies.
Featured Articles
- Five stocks we like better than Regeneron Pharmaceuticals
- Datadog’s Drop Says More About Expectations Than Earnings
- D-Wave’s Quantum Breakthrough Couldn’t Save QBTS From a Sell-Off
- Cloudflare’s Beat-and-Raise Quarter Puts Its AI Edge Story in Focus
- Solventum Nears Inflection Point As It Begins to Unlock Value
Receive News & Ratings for Regeneron Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Regeneron Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
